July 16, 2026New England Journal of MedicineENDURANCE (ECOG-ACRIN E1A11) maintenance randomization (NCT01863550)
Indefinite Lenalidomide Maintenance Fails to Beat 2-Year Fixed Duration in Myeloma
Randomized phase 3 comparison, from the maintenance ("R2") randomization of the ECOG-ACRIN ENDURANCE (E1A11) trial, of indefinite-duration versus fixed 2-year lenalidomide maintenance in 516 standard-risk multiple myeloma patients who did not undergo up-front autologous stem-cell transplantation.